RemeGen Co (FRA:REG) Debt-to-Equity : 0.90 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co Debt-to-Equity?

RemeGen Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €127.5 Mil. RemeGen Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €179.6 Mil. RemeGen Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was €341.2 Mil. RemeGen Co's debt to equity for the quarter that ended in Jun. 2024 was 0.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for RemeGen Co's Debt-to-Equity or its related term are showing as below:

FRA:REG' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.28 Med: 0.04 Max: 0.9
Current: 1.35

During the past 7 years, the highest Debt-to-Equity Ratio of RemeGen Co was 0.90. The lowest was -0.28. And the median was 0.04.

FRA:REG's Debt-to-Equity is ranked worse than
91.34% of 1016 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:REG: 1.35

RemeGen Co Debt-to-Equity Historical Data

The historical data trend for RemeGen Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Debt-to-Equity Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.03

0.37

1.35

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial								0.03	0.16	0.37	0.90	1.35

Competitive Comparison of RemeGen Co's Debt-to-Equity

For the Biotechnology subindustry, RemeGen Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

RemeGen Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

RemeGen Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(44.272	+	117.545)	/	441.441
	=	0.37

RemeGen Co's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(127.527	+	179.56)	/	341.216
	=	0.90

RemeGen Co (FRA:REG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

RemeGen Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.